

The logo for MEDA is rendered in a bold, red, sans-serif font. The letters are thick and blocky, with a slight shadow effect. The background of the entire page is a repeating pattern of light gray, semi-transparent shapes that resemble various types of pills and capsules, some with white lines or markings.

2012 Annual Report

Exhibit 1076
IPR2017-00807

Shareholder information

2013 INTERIM FINANCIAL REPORTS

Interim report January–March	May 7
Interim report January–June	August 2
Interim report January–September	November 8

ANNUAL GENERAL MEETING

Location: Medas's facilities, Pipers väg 2A, Solna, Sweden
Time: 5 PM on Tuesday, May 7, 2013.

SHAREHOLDERS WHO WISH TO PARTICIPATE IN THE MEETING MUST:

- Be registered in the Euroclear Sweden AB share database by April 30, 2013.
- Notify the company by April 30, 2013.
Shareholders may register by postal mail (Meda AB AGM, Box 7835, SE-103 98, Stockholm, Sweden), by phone (+46 8-402 90 49), or via the website at www.meda.se.

REGISTRATION

Notice of attendance must be received no later than April 30, 2013. Registrations shall include name, civil registration or corporate ID number, address, phone number, and number of shares held.

Shareholders represented by proxy must send a power of attorney for the proxy. If the power of attorney is issued by a legal entity, a notarized copy of the corporate registration certificate must also be included. The power of attorney and registration certificate must not be issued more than one year prior to the AGM.

SHARE REGISTRATION

To participate in the AGM, any shareholders whose shares are nominee-registered must temporarily register their shares with Euroclear Sweden AB. The entry must be effected by April 30, 2013.

Address changes should be registered with the appropriate financial institution as soon as possible.

Addresses

HEADQUARTERS:

Meda AB
Box 906 , SE-170 09 Solna, Sweden
Visitors: Pipers väg 2A
Phone: +46 8 630 19 00
Fax: +46 8 630 19 50
E-mail: info@meda.se
www.meda.se

MEDIA AND INVESTOR RELATIONS:

Tel: +46 8 630 19 00
E-mail: IR@meda.se

Contact information for subsidiaries is available at: www.meda.se

Contents

1	Contents	69	Consolidated accounts
2	CEO's report	73	Consolidated notes
4	Milestones	103	Parent company accounts
4	2012 in figures	108	Parent company notes
5	Trends and specialty pharma	118	Proposed allocation of profits
12	Strategy and business development	119	Audit report
14	Meda in brief	120	Financial review
18	Sales and marketing	122	Risk factors
21	Product portfolio	125	The Meda share
37	Drug development	128	Board of directors
40	Manufacture and product supply	130	Senior executives
41	Meda's Sustainability Report 2012	132	Definitions
56	Management report	133	Glossary
62	Corporate governance report		



Anders Lönner at Ernst & Young's "Entrepreneur of The Year" competition in Monte Carlo 2012.

CEO's report

The 2012 fiscal year can be summarized as a year when Meda fully concentrated on continued growth within the boundaries of its business plan. We took carefully planned initiatives in new products and made investments into prioritized growth markets, and combined these with acquisitions of interesting product opportunities.

The Dymista launch began in the US in the second half of 2012. We have received very positive feedback so far, from prescribers and patients alike. It is still too early to draw any definite conclusions, but I am convinced that Dymista presents a unique opportunity for the company. Dymista also received approval in Europe and we expect to begin launch efforts in specific large European markets during the second quarter of 2013.

In 2012, we also significantly expanded Meda's portfolio with additional interesting product launches. A handful of products received new product approvals in Europe, such as Zyclara, Astepro, Acnex, and Edluar. In addition, we finalized several product acquisitions in the US.

Meanwhile, we continue to use the company's global product potential in the OTC area to the best of its advantage, either alone or through partnerships with other pharmaceutical companies. Prescription-free pharmaceuticals display healthy growth figures and now comprise about 25 percent of Meda's total revenue. Another positive effect from this strategic direction is the continued decrease of Meda's dependency on subsidized drugs.

Efforts in prioritized growth markets are also continuing in force, which has also led to a significant expansion of Meda's marketing organizations.

The marketing organizations in Meda's growth markets currently employ about 700 people, an expansion of 300 employees since the beginning of 2012. Meda's combined sales in all growth markets comprise almost 15 percent of the company's total turnover and are displaying robust growth. Russia, the Middle East, China and Turkey currently make up Meda's largest growth regions.

MOVING FORWARD

The pharmaceutical industry is faced with major challenges but Meda is part of segments that will display growth. In a world that is striving after lower pharmaceutical costs on several levels, production costs will become more important. Meda has a good foundation of internal and external production, but we will gradually search for cost effective solutions in production.

In addition, we have a strong cash flow and will take action to continue our acquisitions of interesting products and investments in prioritized markets.

In conclusion, I would like to extend my thanks to all employees for their excellent contribution during 2012. Now we look ahead to the future, to face new exciting challenges.

Anders Lönner
Group President and CEO

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.